AC Immune (NASDAQ:ACIU) Given Buy Rating at BTIG Research

BTIG Research reissued their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research note released on Monday morning,Benzinga reports. BTIG Research currently has a $8.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of AC Immune in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $9.00.

AC Immune Trading Up 3.6%

Shares of NASDAQ ACIU opened at $3.13 on Monday. The business has a 50-day moving average of $3.14 and a 200-day moving average of $3.04. The firm has a market capitalization of $314.28 million, a price-to-earnings ratio of -3.73 and a beta of 1.64. AC Immune has a 12 month low of $1.43 and a 12 month high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Friday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 92.65%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.14 million. On average, analysts predict that AC Immune will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC raised its stake in shares of AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after acquiring an additional 172,796 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of AC Immune by 20.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after purchasing an additional 36,353 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of AC Immune in the 3rd quarter valued at $549,000. Marshall Wace LLP bought a new position in shares of AC Immune during the 4th quarter valued at $586,000. Finally, Sei Investments Co. bought a new position in shares of AC Immune during the 2nd quarter valued at $51,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.